Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frederic Guyon

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Bulletin Du Cancer|March 26, 2023
Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancerPhilipp Harter, Gerhard Bogner, Luis Chiva, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 9, 2026
Comparison of sentinel lymph node mapping with comprehensive lymphadenectomy in p53-mutated endometrial cancer: a prospective, multi-center, non-inferiority, open-label, de-escalation, randomized, controlled trial (Study Protocol - SENTIMETREP53)Cherif Akladios, Lise Lecointre, François Lefebvre, et al.
European Journal of Cancer (Oxford, England : 1990)|June 7, 2019
Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumours: guidelines from the French national network dedicated to rare gynaecological cancersChristine Rousset-Jablonski, Fréderic Selle, Elodie Adda-Herzog, et al.
Bulletin Du Cancer|February 6, 2018
[Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumors: Guidelines from the French national network dedicated to rare gynaecological cancer]Christine Rousset-Jablonski, Fréderic Selle, Elodie Adda-Herzog, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Bulletin Du Cancer|March 26, 2023
Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancerPhilipp Harter, Gerhard Bogner, Luis Chiva, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 9, 2026
Comparison of sentinel lymph node mapping with comprehensive lymphadenectomy in p53-mutated endometrial cancer: a prospective, multi-center, non-inferiority, open-label, de-escalation, randomized, controlled trial (Study Protocol - SENTIMETREP53)Cherif Akladios, Lise Lecointre, François Lefebvre, et al.
European Journal of Cancer (Oxford, England : 1990)|June 7, 2019
Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumours: guidelines from the French national network dedicated to rare gynaecological cancersChristine Rousset-Jablonski, Fréderic Selle, Elodie Adda-Herzog, et al.
Bulletin Du Cancer|February 6, 2018
[Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumors: Guidelines from the French national network dedicated to rare gynaecological cancer]Christine Rousset-Jablonski, Fréderic Selle, Elodie Adda-Herzog, et al.
Pageof 4